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Continuous processes can be particularly efficient for production of biologicals that are required in large amounts 
such as viral vaccines. One virus that has received much clinical attention is Modified Vaccinia Ankara virus 
(MVA), which is a potential platform for expression of recombinant viral antigens and can be used as a vector in 
gene therapy [1]. Recently, a new MVA virus strain has been successfully propagated at high yields in non-
aggregated avian suspension cells [2] allowing the production of MVA virus in continuous bioreactors. MVA is a 
lytic DNA virus and therefore, continuous production strategies can be implemented using two-stage bioreactor 
systems, where cell growth and virus propagation occur in separated vessels [3]. However, a possible drawback 
for continuous virus production is the presence of defective interfering particles among the virus population that 
cause oscillations in virus levels and low production yields [3], known as Von Magnus effect.   
 
In this work, continuous production of MVA virus in a two-stage bioreactor (TSB) set-up (two 1 L stirred tank 
bioreactors) was evaluated. Subsequently, the set-up was scaled down to a non-instrumented semi-continuous 
cultivation system (two shaker flasks; small-scale culture, SSC) as approximation to a continuous cultivation [4] 
that would facilitate TSB screening. The virus strain MVA.CR19 and the duck cell line AGE1.CR.pIX (both from 
ProBioGen, Berlin) were used. The TSB system involved a bioreactor for cell growth and a second bioreactor in 
series for virus propagation [3]. The SSC system consisted of two shaker flasks, one for cell growth (120 mL 
working volume) and another for virus propagation (different residence times). Harvest, cell transfer, and addition 
of fresh medium were done manually twice a day. 
 
Continuous production of MVA-CR19 was maintained for 18 d with the TSB system. Virus titers showed 7 d of 
transient phase, followed by stable titers that suggested the absence of a Von Magnus effect over 18 d. A total 
production capacity of 2x1010 viruses/day was estimated (4x1010 viruses/day estimated for batch). The space-time 
yield of the TSB approached that of 2 parallel batches at 11 d post infection. The process was scaled down to the 
SSC system that resulted in stable production of cells, and virus titers that approached the dynamics and values 
obtained with the TSB system. Additional cultivations with the SSC system showed that different residence times 
in the virus bioreactor could influence virus titers.  
 
Overall, it was demonstrated that continuous production of MVA.CR19 virus in a TSB system is feasible. Also, a 
small scale two-stage semi-continuous cultivation was successfully established as a faster and cheaper tool for 
screening the TSB systems before scale-up. 
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